VERISOL®- Ingredient-Specific Clinical Evidence

Molecular Characteristics of VERISOL®

1. Defined Peptide Composition

2. Oral Bioavailability

3. Targeted Dermal Activity

4. Mechanistic Differentiation

Implication:

What VERISOL Evidence Supports

Study Population Duration Dose Design Key Outcomes (% Improvements)
Proksch et al., 2014 (Elasticity) 69 women (35–55) 8 weeks 2.5 g / 5 g RCT, DB, PC ↑ Skin elasticity (significant, sustained)
Proksch et al., 2014 (Wrinkles + ECM) 114 women (45–65) 8 weeks 2.5 g RCT, DB, PC ↓ Wrinkles (~20%), ↑ Procollagen I (+65%), ↑ Elastin (+18%)
Schunck et al., 2015 (Cellulite/ECM) 105 women (24–50) 6 months 2.5 g RCT, DB, PC ↓ Cellulite, ↑ Dermal density (p<0.05)
Hexsel et al., 2017 (Nails) 25 women 24 weeks 2.5 g Open-label ↑ Nail growth (+12%), ↓ breakage (-42%)
Oesser et al., 2020 (Hair) 44 women 16 weeks 2.5 g PC trial ↑ Hair thickness (+1.93 μm), ↑ proliferation (+31%)
Proksch et al., 2020 (Skin – variant) 76 women 8 weeks 5 g RCT, PC ↑ Elasticity, ↓ wrinkles (~15%)

What VERISOL Evidence Supports

Conclusion